Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Patient Advocacy Groups Take In Millions From Drugmakers. Is There A Payback?

    Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year, reveals a new database logging 12,000 donations from large publicly traded drugmakers to such organizations.

    10 April 2018 | Washington Post
  • My PrEP story: Patrick (part 2)

    In his second My PrEP Story blog Dr. Patrick Baxter talks about being on Gilead’s DISCOVER Trial. What’s the trial attempting to do? And why the lack of community consultation? And is he really using PrEP?

    10 April 2018 | Prepster
  • Why do new medicines cost so much, and what can we do about it?

    The cost of new drugs is putting increasing pressure on people in both rich and poor countries. We explain why it’s a burning issue.

    10 April 2018 | The Guardian
  • A Cheaper Version of Truvada Is Hitting the US Market: Here's Why It Might Not Lower Costs

    Coming to U.S. pharmacies this month is Cimduo, from drugmaker Mylan. It's essentially a copycat of Truvada (TDF/FTC), but there's good reason to believe that, despite its lower price, Mylan just won't catch on. And the reasons point to the bigger issue of why it's so hard in general to bring down to earth the price of HIV drugs.

    04 April 2018 | The Body
  • Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S.

    The U.S. Food and Drug Administration (FDA) approved Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen (STR).

    03 April 2018 | Mylan press release
  • ViiV Healthcare gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe

    The European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.

    23 March 2018 | ViiV press release
  • Argentine NGO objects to antiretroviral patent request

    NGO requests rejection of Gilead Sciences patent request for TAF (Tenofovir Alafenamide fumarate). It alleges it would increase costs, says there is no basis for request.

    23 March 2018 | Sci Dev Net
  • Gilead Sciences: The Future Is Complicated

    Gilead Sciences mix of slumping sales, future product speculation, and cash position make for a confusing investment. Sales of its Hepatitis lineup are consistently falling, while HIV sales growth fails to make up the difference.

    14 March 2018 | Seeking Alpha
  • J&J, Macleods in talks for licence deal of tuberculosis drug

    Mumbai-based Macleods Pharmaceuticals and US drug giant Johnson & Johnson(J&J) are in talks for a voluntary licence deal for the tuberculosis drug Bedaquiline, EThas learnt.

    13 March 2018 | Economic Times
  • Two new generic HIV regimens to be introduced in US

    The global pharmaceutical company Mylan announced today that it will be introducing two new HIV treatment regimens — Symfi Lo and Cimduo — in the United States. Both treatments were approved by the FDA last month.

    06 March 2018 | Healio
More news


Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.